Trial · NCT06112743
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Composite of maximum left atrial volume index (LAVI) and left ventricular mass index (LVMI) at Week 48 | At week 48 | Participants achieving both of the following criteria at Week 48 cardiac magnetic resonance imaging (CMR) assessment: * A decrease of at least 5 mL/m2 in maximum LAVI from baseline * A decrease of at least 5 g/m2 in LVMI from baseline |
| Secondary | Proportion of participants who had at least 1 class of improvement from baseline in New York Heart Association (NYHA) class at Week 48 | At week 48 | |
| Secondary | Change from baseline in maximum left atrial volume index (LAVI) at Week 48 | At week 48 | |
| Secondary | Change from baseline in left ventricular mass index (LVMI) at Week 48 | At week 48 | |
| Secondary | Incidence of major adverse cardiac events (MACE) | Up to 48 weeks | |
| Secondary | Incidence of MACE-expanded events | Up to 48 weeks | |
| Secondary | All-cause mortality | Up to 48 weeks | |
| Secondary | Incidence of heart failure (HF) events | Up to 48 weeks | |
| Secondary | Incidence of HF events with systolic dysfunction | Up to 48 weeks | |
| Secondary | Incidence of atrial fibrillation (AF)/atrial flutter | Up to 48 weeks | |
| Secondary | Incidence of cardiovascular (CV) mortality | Up to 48 weeks | |
| Secondary | Incidence of ventricular tachyarrhythmias | Up to 48 weeks | |
| Secondary | Incidence of nonvasovagal syncope and seizures | Up to 48 weeks | |
| Secondary | Incidence of treatment emergent adverse events (TEAEs) | Up to 48 weeks | |
| Secondary | Severity of TEAEs | Up to 48 weeks | |
| Secondary | Incidence of treatment emergent serious adverse events (SAEs) | Up to 48 weeks | |
| Secondary | TEAEs leading to discontinuation from study intervention | Up to 48 weeks | |
| Secondary | TEAEs leading to laboratory abnormalities | Up to 48 weeks |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06112743/registered